Levamisole-associated multifocal inflammatory encephalopathy: clinical and MRI characteristics, and diagnostic algorithm.


Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Jan 2023
Historique:
received: 02 10 2022
revised: 12 11 2022
accepted: 15 11 2022
pubmed: 1 12 2022
medline: 2 2 2023
entrez: 30 11 2022
Statut: ppublish

Résumé

Levamisole-associated multifocal inflammatory encephalopathy (LAMIE) is a devastating adverse effect of levamisole (LEV) treatment. In Russia, people often use LEV without a doctor's prescription for anthelmintic prophylaxis. LAMIE often misdiagnosed as the first episode of MS or acute disseminated encephalomyelitis (ADEM). The aim of our study was to describe clinical, laboratory and morphological characteristics of LAMIE, magnetic resonance imaging (MRI) patterns and create an algorithm for the differential diagnosis. This study was a prospective observational study with retrospective analysis of cases. It was performed at two hospitals with ambulatory service for MS. We included 43 patients with LAMIE with follow-up was from 1 year to 5 years. Age was 19-68 y.o. with female predominance. The most typical manifestations of LAMIE were cerebellar, pyramidal and cognitive symptoms, and majority of patients had biphasic course of the disease. Three main types of MRI patterns were described: ADEM-like, MS-like, atypical demyelination. About 40% of patients had CSF specific oligoclonal bands synthesis, but only 20 % of them converted to MS during the period from 1 month until 2 years. The CSF albumin levels and immunoglobulin G index were elevated in LAMIE patients compared to reference values. We described results of brain biopsy in two cases. Therefore LAMIE should be considered in patients with demyelinating or inflammatory conditions with biphasic onset of the disease and variable MRI presentation.

Identifiants

pubmed: 36450175
pii: S2211-0348(22)00922-1
doi: 10.1016/j.msard.2022.104418
pii:
doi:

Substances chimiques

Levamisole 2880D3468G

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104418

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

V Fominykh (V)

Institute of Higher Nervous Activity and Neurophysiology, Butlerova street 5a, Moscow 117485, Russia. Electronic address: hydrohinon@mail.ru.

D Averchenkov (D)

Bujanov Moscow City Clinical Hospital, Moscow, Russia.

A Volik (A)

Institute of Higher Nervous Activity and Neurophysiology, Butlerova street 5a, Moscow 117485, Russia; Federal State Budget Educational Institution of Higher Education M.V.Lomonosov Moscow State University, Moscow, Russia.

E Popova (E)

City Clinical Hospital № 24, Moscow, Russia.

V Bryukhov (V)

Research Center of Neurology, Moscow, Russia.

V Nazarov (V)

Research Center of Neurology, Moscow, Russia; Pavlov First Saint Petersburg Medical University, Saint Petersburg, Russia.

A Moshnikova (A)

Pavlov First Saint Petersburg Medical University, Saint Petersburg, Russia.

N Arzumanian (N)

Bujanov Moscow City Clinical Hospital, Moscow, Russia.

A Tatarenko (A)

Bujanov Moscow City Clinical Hospital, Moscow, Russia.

V Nechaev (V)

Bujanov Moscow City Clinical Hospital, Moscow, Russia.

O Manuylova (O)

Bujanov Moscow City Clinical Hospital, Moscow, Russia.

S Lapin (S)

Pavlov First Saint Petersburg Medical University, Saint Petersburg, Russia.

L Brylev (L)

Institute of Higher Nervous Activity and Neurophysiology, Butlerova street 5a, Moscow 117485, Russia; Bujanov Moscow City Clinical Hospital, Moscow, Russia; Moscow Research and Clinical Center for Neuropsychiatry, Moscow Healthcare Department, Russia.

A Guekht (A)

Moscow Research and Clinical Center for Neuropsychiatry, Moscow Healthcare Department, Russia; Pirogov Russian National Research Medical University, Moscow, Russia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH